Ann Surg Treat Res.  2025 May;108(5):317-324. 10.4174/astr.2025.108.5.317.

Establishment of an orthotopic nude mouse model for recurrent pancreatic cancer after complete resection: an experimental animal study

• Park SE
• Hong TH

• KMID: 2567925
• DOI: http://doi.org/10.4174/astr.2025.108.5.317

Abstract

Purpose
This study created a nude mouse model to study pancreatic cancer recurrence. Circumstances leading to the highest recurrence rates after curative surgery were also analyzed.
Methods
A total of 135 nude mice were divided into 3 groups: sham, metastasis, and resection (45 mice in each group). In sham and resection groups, AsPc-1 cells suspended in a synthetic extracellular matrix were injected into the tail of the pancreas of each mouse. In the metastasis group, cells were injected into the spleen. After 3 weeks, the resection group underwent distal pancreatectomy and the metastasis group underwent diagnostic laparotomy to confirm metastasis. To assess disease recurrence, the resection group was monitored weekly using luminescence imaging. Diagnostic exploration was conducted 3 weeks after surgery. Recurrence rate was evaluated and histological examination was performed for the resection group.
Results
Among 45 mice, 43 developed cancerous masses in the tail of the pancreas without invading adjacent organs 3 weeks after the initial orthotopic injection. Of those 43 mice, one died due to intraoperative bleeding during complete surgical resection. Pancreatic cancer recurrence was observed in 37 of 42 mice (88.1%) at an average of 21.8 ± 2.2 days. Histological examination showed high nuclear pleomorphism and neoangiogenesis.
Conclusion
We developed an efficient model that could demonstrate recurrence after complete resection of pancreatic cancer. By confirming that recurrence occurs after surgery using this protocol, our model is expected to contribute to the development of various treatment strategies.

Keyword

Mice; Pancreatic neoplasms; Pancreatectomy; Prognosis; Recurrence

Reference

1. Han Z, Shang W, Liang X, Yan H, Hu M, Peng L, et al. An innovation for treating orthotopic pancreatic cancer by preoperative screening and imaging-guided surgery. Mol Imaging Biol. 2019; 21:67–77. PMID: 29858735.

2. Eibl G, Reber HA. A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. Pancreas. 2005; 31:258–262. PMID: 16163058.

3. Torgenson MJ, Shea JE, Firpo MA, Dai Q, Mulvihill SJ, Scaife CL. Natural history of pancreatic cancer recurrence following “curative” resection in athymic mice. J Surg Res. 2008; 149:57–61. PMID: 18222475.

4. Chai MG, Kim-Fuchs C, Angst E, Sloan EK. Bioluminescent orthotopic model of pancreatic cancer progression. J Vis Exp. 2013; (76):50395. PMID: 23852391.

5. Suklabaidya S, Dash P, Das B, Suresh V, Sasmal PK, Senapati S. Experimental models of pancreatic cancer desmoplasia. Lab Invest. 2018; 98:27–40. PMID: 29155423.

6. Bisht S, Feldmann G. Animal models for modeling pancreatic cancer and novel drug discovery. Expert Opin Drug Discov. 2019; 14:127–142. PMID: 30657339.

7. Satake T, Suetsugu A, Nakamura M, Hasegawa K, Kunisada T, Shimizu M, et al. Differential organ-targeting and cellular characteristics of metastatic human pancreatic cancer cell lines in mouse models. Anticancer Res. 2018; 38:1927–1935. PMID: 29599308.

8. Pang TC, Xu Z, Mekapogu AR, Pothula S, Becker TM, Goldstein D, et al. An orthotopic resectional mouse model of pancreatic cancer. J Vis Exp. 2020; (163):DOI: 10.3791/61726.

9. Miao JX, Wang JY, Li HZ, Guo HR, Dunmall LS, Zhang ZX, et al. Promising xenograft animal model recapitulating the features of human pancreatic cancer. World J Gastroenterol. 2020; 26:4802–4816. PMID: 32921958.

10. Hotz HG, Reber HA, Hotz B, Yu T, Foitzik T, Buhr HJ, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas. 2003; 26:e89–e98. PMID: 12717279.

11. Giri B, Ferrantella A, Sharma P, Jain T, Jacob HK, Modi S, et al. An immunocompetent model of pancreatic cancer resection and recurrence. J Gastrointest Surg. 2021; 25:1271–1279. PMID: 32542554.

12. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009; 35:600–604. PMID: 19131205.

13. Huang X, Zhao F, Wu Q, Wang Z, Ren H, Zhang Q, et al. KIF2C facilitates tumor growth and metastasis in pancreatic ductal adenocarcinoma. Cancers (Basel). 2023; 15:1502. PMID: 36900292.

14. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013; 6:321–337.

15. Guzmán EA, Johnson JD, Linley PA, Gunasekera SE, Wright AE. A novel activity from an old compound: manzamine A reduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis. Invest New Drugs. 2011; 29:777–785. PMID: 20352293.

16. Dai L, Lu C, Yu XI, Dai LJ, Zhou JX. Construction of orthotopic xenograft mouse models for human pancreatic cancer. Exp Ther Med. 2015; 10:1033–1038. PMID: 26622435.

17. Ahn KS, Hwang JY, Han HS, Kim ST, Hwang I, Chun YO. The impact of acute inf lammation on progression and metastasis in pancreatic cancer animal model. Surg Oncol. 2018; 27:61–69. PMID: 29549905.

18. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860–867. PMID: 12490959.

19. Manrai M, Tilak TV, Dawra S, Srivastava S, Singh A. Current and emerging therapeutic strategies in pancreatic cancer: challenges and opportunities. World J Gastroenterol. 2021; 27:6572–6589. PMID: 34754153.

20. Karim SA, Abdulla KS, Abdulkarim QH, Rahim FH. The outcomes and complications of pancreaticoduodenectomy (Whipple procedure): cross sectional study. Int J Surg. 2018; 52:383–387. PMID: 29438817.

21. Camajani E, Feraco A, Verde L, Moriconi E, Marchetti M, Colao A, et al. Ketogenic diet as a possible non-pharmacological therapy in main endocrine diseases of the female reproductive system: a practical guide for nutritionists. Curr Obes Rep. 2023; 12:231–249. PMID: 37405618.